Amedisys (NASDAQ:AMED) Hits New 1-Year High at $97.42

Amedisys, Inc. (NASDAQ:AMED) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $97.42 and last traded at $97.18, with a volume of 603345 shares changing hands. The stock had previously closed at $96.74.

Analyst Ratings Changes

AMED has been the subject of a number of research analyst reports. Royal Bank of Canada lifted their price target on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 25th. William Blair downgraded Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday. Cantor Fitzgerald reiterated a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday, April 25th. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Finally, Raymond James reiterated a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $100.67.

Amedisys Stock Performance

The business has a 50 day moving average price of $93.31 and a 200 day moving average price of $93.46. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.00 earnings per share. As a group, equities analysts anticipate that Amedisys, Inc. will post 4.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AMED. Banque Cantonale Vaudoise bought a new position in Amedisys in the first quarter valued at about $60,000. Covestor Ltd lifted its position in shares of Amedisys by 134.2% during the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after buying an additional 447 shares in the last quarter. Cetera Trust Company N.A purchased a new position in shares of Amedisys during the 4th quarter valued at about $215,000. CWM LLC lifted its position in shares of Amedisys by 40.4% during the 4th quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock valued at $250,000 after buying an additional 757 shares in the last quarter. Finally, Contravisory Investment Management Inc. purchased a new position in shares of Amedisys during the 4th quarter valued at about $258,000. 94.36% of the stock is owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.